Holen Sie sich die Stockscreener-App
4.79
4.20%
-0.21
Handel nachbörslich:
4.79
Schlusskurs vom Vortag:
$5.00
Offen:
$4.97
24-Stunden-Volumen:
134.93K
Relative Volume:
0.24
Marktkapitalisierung:
$226.16M
Einnahmen:
$31.37M
Nettoeinkommen (Verlust:
$-53.77M
KGV:
-3.295
EPS:
-1.4537
Netto-Cashflow:
$-49.02M
1W Leistung:
-1.03%
1M Leistung:
-13.85%
6M Leistung:
-69.76%
1J Leistung:
-79.87%
1-Tages-Spanne:
$4.75
$5.10
1-Wochen-Bereich:
$4.70
$5.16
52-Wochen-Spanne:
$4.06
$27.72
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
Firmenname
Silence Therapeutics Plc Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie SLN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLN
Silence Therapeutics Plc Adr
|
4.79 | 226.16M | 31.37M | -53.77M | -49.02M | -1.4537 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-11 | Eingeleitet | Goldman | Sell |
| 2024-12-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2024-09-03 | Eingeleitet | Jefferies | Buy |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
Silence Therapeutics Plc Adr Aktie (SLN) Neueste Nachrichten
BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - GlobeNewswire Inc.
Goldman Sachs cuts Silence Therapeutics stock rating to Sell By Investing.com - Investing.com South Africa
Should investors be concerned about Silence Therapeutics Plc ADR (SLN)? - US Post News
Akoya Biosciences Inc (AKYA)’s Day in Review: Closing at 2.34, Down by -4.88 - The Dwinnex
Cloudflare Inc’s (NET) Stock: A 29.10% Simple Moving Average for the Past 20 Days - The News Heater
Silence Therapeutics's SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Silence Therapeutics's SWOT analysis: stock poised for growth amid challenges - Investing.com
H.C. WAINWRIGHT MAINTAINS $75 TARGET ON SILENCE THERAPEUTICS STOCK By Investing.com - Investing.com South Africa
European Equities Traded in US as American Depositary Receipts Surge on Monday - MSN
Top 3 Health Care Stocks That May Explode In Q4 - Benzinga
Silence Therapeutics' SWOT analysis: stock's potential in RNAi therapeutics - Investing.com
Silence Therapeutics' SWOT analysis: RNAi stock poised for growth amid clinical progress - Investing.com India
Silence Therapeutics announces additional results from SANRECO study - TipRanks
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels - MSN
GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study - Yahoo Finance
United States shares mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com
Silence Therapeutics weakness after AHA updates ‘overdone,’ says BMO Capital - TipRanks
SILENCE THERAPEUTICS PLC SPONSORED ADR trading resumes - TipRanks
Top 3 Health Care Stocks You'll Regret Missing In Q4 - Benzinga
Silence Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Silence Therapeutics: Rising Assets Amid Growing Losses - TipRanks
Novartis Gets CHMP Recommendation for Kisqali in Broader Population - Yahoo Finance
80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight - 新浪香港
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty - Yahoo Finance
Silence Therapeutics's SWOT analysis: stock poised for growth in genetic medicine By Investing.com - Investing.com South Africa
Silence Therapeutics's SWOT analysis: stock poised for growth in genetic medicine - Investing.com
Biogen's Lupus Candidate Meets Key Goals in Phase III Study - Yahoo Finance
CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease - Yahoo Finance
It makes sense and dollars to buy Silence Therapeutics Plc ADR (SLN) stock - SETE News
Silence Therapeutics Plc ADR (SLN) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
What Did We Find About Insider Trading At Silence Therapeutics Plc ADR (NASDAQ: SLN)? - Stocks Register
Silence Therapeutics shares start at Buy from Jefferies, reflecting strong clinical data - Investing.com UK
H.C. Wainwright reiterates Buy on Silence Therapeutics stock amid strong trial results By Investing.com - Investing.com South Africa
GSK's RSV Vaccine Arexvy Gets EU Nod for Adults Aged 50-59 Years - Yahoo Finance
The 3 Best Gene Editing Stocks to Buy in August 2024 - Markets Insider
Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last? - Yahoo Finance
Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains? - Yahoo Finance
Here's Why Momentum in Silence Therapeutics PLC Sponsored ADR (SLN) Should Keep going - MSN
Does Silence Therapeutics PLC Sponsored ADR (SLN) Have the Potential to Rally 187.05% as Wall Street Analysts Expect? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Silence Therapeutics Plc ADR (SLN-Q) QuotePress Release - The Globe and Mail
Genfit (NASDAQ:GNFT) Stock Quotes, Forecast and News Summary - Benzinga
The Daily Biotech Pulse: Pfizer, BioNTech Begin European Filing For Coronavirus Vaccine, Y-mAbs BLA Rejected, GlycoMimetics Granted Rare Pediatric Disease Designation - Yahoo Finance
Silence Therapeutics (SLN) - Zacks Investment Research
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Finanzdaten der Silence Therapeutics Plc Adr-Aktie (SLN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):